Go Pro
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free BIO Stock Alerts

Bio-Rad Laboratories (BIO) Competitors

Bio-Rad Laboratories logo
$301.93 -2.43 (-0.80%)
Closing price 07/20/2026 03:59 PM Eastern
Extended Trading
$292.91 -9.02 (-2.99%)
As of 08:46 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BIO vs. RGEN, TECH, A, AMN, and BIO.B

Should you buy Bio-Rad Laboratories stock or one of its competitors? MarketBeat compares Bio-Rad Laboratories with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bio-Rad Laboratories include Repligen (RGEN), Bio-Techne (TECH), Agilent Technologies (A), AMN Healthcare Services (AMN), and Bio-Rad Laboratories (BIO.B). These companies are all part of the "medical" sector.

How does Bio-Rad Laboratories compare to Repligen?

Bio-Rad Laboratories (NYSE:BIO) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Repligen has a net margin of 6.73% compared to Bio-Rad Laboratories' net margin of 6.52%. Repligen's return on equity of 4.88% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Repligen 6.73%4.88%3.48%

Bio-Rad Laboratories has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Comparatively, Repligen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

In the previous week, Repligen had 2 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 8 mentions for Repligen and 6 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.07 beat Bio-Rad Laboratories' score of 0.49 indicating that Repligen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Repligen
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.13$759.90M$6.0749.74
Repligen$738.26M11.12$48.89M$0.90161.66

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by company insiders. Comparatively, 0.6% of Repligen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bio-Rad Laboratories currently has a consensus target price of $303.33, indicating a potential upside of 0.46%. Repligen has a consensus target price of $165.00, indicating a potential upside of 13.41%. Given Repligen's stronger consensus rating and higher possible upside, analysts clearly believe Repligen is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Repligen
1 Sell rating(s)
2 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.89

Summary

Repligen beats Bio-Rad Laboratories on 12 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Techne?

Bio-Rad Laboratories (NYSE:BIO) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential upside of 0.46%. Bio-Techne has a consensus price target of $68.08, indicating a potential downside of 4.97%. Given Bio-Rad Laboratories' higher probable upside, equities research analysts clearly believe Bio-Rad Laboratories is more favorable than Bio-Techne.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Bio-Techne
1 Sell rating(s)
13 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.12

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 98.9% of Bio-Techne shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 1.3% of Bio-Techne shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bio-Techne has a net margin of 9.05% compared to Bio-Rad Laboratories' net margin of 6.52%. Bio-Techne's return on equity of 13.57% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Bio-Techne 9.05%13.57%10.66%

Bio-Rad Laboratories has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Bio-Techne has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 6 articles in the media. Bio-Techne's average media sentiment score of 0.82 beat Bio-Rad Laboratories' score of 0.49 indicating that Bio-Techne is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Bio-Techne
4 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Bio-Rad Laboratories has higher revenue and earnings than Bio-Techne. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.13$759.90M$6.0749.74
Bio-Techne$1.21B9.26$73.40M$0.69103.83

Summary

Bio-Techne beats Bio-Rad Laboratories on 10 of the 15 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Agilent Technologies?

Bio-Rad Laboratories (NYSE:BIO) and Agilent Technologies (NYSE:A) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Agilent Technologies has a net margin of 19.55% compared to Bio-Rad Laboratories' net margin of 6.52%. Agilent Technologies' return on equity of 24.33% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Agilent Technologies 19.55%24.33%12.99%

Bio-Rad Laboratories currently has a consensus target price of $303.33, suggesting a potential upside of 0.46%. Agilent Technologies has a consensus target price of $159.35, suggesting a potential upside of 22.07%. Given Agilent Technologies' stronger consensus rating and higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Agilent Technologies
0 Sell rating(s)
4 Hold rating(s)
13 Buy rating(s)
2 Strong Buy rating(s)
2.89

In the previous week, Agilent Technologies had 9 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 15 mentions for Agilent Technologies and 6 mentions for Bio-Rad Laboratories. Agilent Technologies' average media sentiment score of 1.20 beat Bio-Rad Laboratories' score of 0.49 indicating that Agilent Technologies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agilent Technologies
13 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Agilent Technologies has higher revenue and earnings than Bio-Rad Laboratories. Agilent Technologies is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.13$759.90M$6.0749.74
Agilent Technologies$6.95B5.31$1.30B$4.9826.21

Bio-Rad Laboratories has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the broader market.

65.2% of Bio-Rad Laboratories shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Agilent Technologies beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to AMN Healthcare Services?

Bio-Rad Laboratories (NYSE:BIO) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

In the previous week, Bio-Rad Laboratories and Bio-Rad Laboratories both had 6 articles in the media. Bio-Rad Laboratories' average media sentiment score of 0.49 beat AMN Healthcare Services' score of 0.08 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
5 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AMN Healthcare Services
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bio-Rad Laboratories has higher earnings, but lower revenue than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.13$759.90M$6.0749.74
AMN Healthcare Services$2.73B0.48-$95.70M-$0.87N/A

Bio-Rad Laboratories currently has a consensus price target of $303.33, indicating a potential upside of 0.46%. AMN Healthcare Services has a consensus price target of $27.00, indicating a potential downside of 19.93%. Given Bio-Rad Laboratories' higher possible upside, research analysts clearly believe Bio-Rad Laboratories is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
AMN Healthcare Services
2 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.22

65.2% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 30.3% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Bio-Rad Laboratories has a net margin of 6.52% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
AMN Healthcare Services -0.95%18.01%5.19%

Bio-Rad Laboratories has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Summary

Bio-Rad Laboratories beats AMN Healthcare Services on 9 of the 15 factors compared between the two stocks.

How does Bio-Rad Laboratories compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories6.52% 3.56% 2.49%
Bio-Rad Laboratories 6.52%3.56%2.49%

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Bio-Rad Laboratories has a consensus target price of $303.33, indicating a potential upside of 0.46%. Given Bio-Rad Laboratories' stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Bio-Rad Laboratories
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Bio-Rad Laboratories had 6 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 6 mentions for Bio-Rad Laboratories and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.49 beat Bio-Rad Laboratories' score of 0.00 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Company Overall Sentiment
Bio-Rad Laboratories Neutral
Bio-Rad Laboratories Neutral

Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.20$759.90M$6.0750.97
Bio-Rad Laboratories$2.58B3.13$759.90M$6.0749.74

Bio-Rad Laboratories has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market.

Summary

Bio-Rad Laboratories beats Bio-Rad Laboratories on 8 of the 10 factors compared between the two stocks.

Get Bio-Rad Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for BIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BIO vs. The Competition

Export
MetricBio-Rad LaboratoriesMED PRODUCTS IndustryMedical SectorNYSE Exchange
Market Cap$8.15B$8.90B$6.89B$23.42B
Dividend YieldN/A2.48%2.67%4.15%
P/E Ratio49.7416.0427.0730.65
Price / Sales3.136.77515.7220.32
Price / Cash30.3718.5526.6818.81
Price / Book1.093.2610.624.74
Net Income$759.90M$230.22M$3.60B$1.07B
7 Day Performance1.16%-1.77%-1.26%-0.46%
1 Month Performance6.76%-1.97%1.07%0.67%
1 Year Performance23.24%-0.92%23.63%16.45%

Bio-Rad Laboratories Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BIO
Bio-Rad Laboratories
0.9434 of 5 stars		$301.93
-0.8%		$303.33
+0.5%		+22.6%$8.15B$2.58B49.747,450
RGEN
Repligen
3.1944 of 5 stars		$144.88
+0.4%		$165.00
+13.9%		+25.2%$8.14B$738.26M160.982,000
TECH
Bio-Techne
2.4064 of 5 stars		$71.36
+0.1%		$68.08
-4.6%		+37.7%$11.16B$1.22B103.423,100
A
Agilent Technologies
4.9715 of 5 stars		$134.01
-0.2%		$159.35
+18.9%		+14.5%$37.93B$6.95B26.9118,100
AMN
AMN Healthcare Services
1.5661 of 5 stars		$33.97
+4.9%		$27.00
-20.5%		+70.0%$1.26B$2.73BN/A2,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:BIO) was last updated on 7/21/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel
Elon's new "super startup"
Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...
Banyan Hill Publishing | Sponsoredtc pixel